UPCC 02818: A Phase I/IB Study of Avelumab in Combination with Gemcitabine for Advanced Renal Cell Carcinoma with Sarcomatoid Differentiation
Enrolling By Invitation
99 years or below
All
Phase
1
30 participants needed
1 Location
Brief description of study
This study is being done because doctors are trying to develop better methods for treating kidney cancer that has spread to other organs in the body. This study will evaluate the initial safety and effectiveness of an investigational drug, avelumab, given in combination with a chemotherapy drug (gemcitabine) that is sometimes used to treat certain kidney cancers.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: renal cell carcinoma
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 829195
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
